Key points:


• Enfortumab vedotin: Learn about the common side effects such as skin toxicities, hyperglycemia, and neuropathy, and how to manage them effectively in clinical practice.
• Sacituzumab govitecan: Explore the challenges of neutropenia, diarrhea, and fatigue, and the importance of individualized patient care.
• Trastuzumab deruxtecan (TDXD): Understand the critical side effects including nausea, fatigue, and interstitial lung disease (ILD), and the strategies for prevention and management.
In this episode of the Oncology Brothers, dived into the complexities of managing side effects associated with antibody drug conjugates (ADCs). Drs. Rahul & Rohit Gosain are joined by esteemed guests Dr. Tian Zhang, a GU medical oncologist from UT Southwestern, and Dr. Erika Hamilton from the Sarah Cannon Research Institute.
Episode kicked off with the discussion by focusing on Enfortumab, which targets Nectin-4 and has recently became the standard of care for metastatic bladder cancer. Dr. Zhang highlights the common side effects, including skin toxicities, hyperglycemia, and neuropathy, and shares strategies for managing these issues in the clinic, such as dose reductions and careful monitoring of blood sugar levels.
Next, attention was shifted to Sacituzumab govitecan, which targets Trop-2 and is approved for various cancers, including triple-negative breast cancer. Dr. Hamilton emphasized the importance of recognizing that each ADC has a unique side effect profile. She discussed the challenges of managing neutropenia and diarrhea, as well as the need for individualized treatment plans.
Finally, covered Trastuzumab deruxtecan, an ADC targeting HER2, where nausea and interstitial lung disease (ILD) are significant concerns. Dr. Hamilton provides insights into effective anti-emetic strategies and the critical need for vigilance regarding ILD, stressing that even mild symptoms warrant careful monitoring.
Throughout the episode, all the speakers stressed the importance of understanding the distinct side effects of each ADC and the need for proactive management strategies to enhance patient care. We hope this discussion provided our listeners with valuable insights to navigate the complexities of toxicity management in their practice. Thank you for joining us on this informative journey!